Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation. |
Domain |
PF07654 Immunoglobulin C1-set domain PF00969 Class II histocompatibility antigen |
Function |
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. |
Biological Process |
GO:0001819 positive regulation of cytokine production GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002495 antigen processing and presentation of peptide antigen via MHC class II GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0007159 leukocyte cell-cell adhesion GO:0019882 antigen processing and presentation GO:0019884 antigen processing and presentation of exogenous antigen GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0032609 interferon-gamma production GO:0032649 regulation of interferon-gamma production GO:0032729 positive regulation of interferon-gamma production GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0034341 response to interferon-gamma GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042110 T cell activation GO:0042129 regulation of T cell proliferation GO:0045785 positive regulation of cell adhesion GO:0046651 lymphocyte proliferation GO:0048002 antigen processing and presentation of peptide antigen GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050851 antigen receptor-mediated signaling pathway GO:0050852 T cell receptor signaling pathway GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0060333 interferon-gamma-mediated signaling pathway GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071346 cellular response to interferon-gamma GO:0071593 lymphocyte aggregation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion |
Molecular Function |
GO:0003823 antigen binding GO:0033218 amide binding GO:0042277 peptide binding GO:0042605 peptide antigen binding |
Cellular Component |
GO:0005765 lysosomal membrane GO:0005802 trans-Golgi network GO:0010008 endosome membrane GO:0012507 ER to Golgi transport vesicle membrane GO:0030133 transport vesicle GO:0030134 ER to Golgi transport vesicle GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0030139 endocytic vesicle GO:0030176 integral component of endoplasmic reticulum membrane GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030662 coated vesicle membrane GO:0030665 clathrin-coated vesicle membrane GO:0030666 endocytic vesicle membrane GO:0030669 clathrin-coated endocytic vesicle membrane GO:0031227 intrinsic component of endoplasmic reticulum membrane GO:0031984 organelle subcompartment GO:0032588 trans-Golgi network membrane GO:0042611 MHC protein complex GO:0042613 MHC class II protein complex GO:0044440 endosomal part GO:0045334 clathrin-coated endocytic vesicle GO:0071556 integral component of lumenal side of endoplasmic reticulum membrane GO:0098552 side of membrane GO:0098553 lumenal side of endoplasmic reticulum membrane GO:0098791 Golgi subcompartment GO:0098852 lytic vacuole membrane |
KEGG |
hsa04145 Phagosome hsa04514 Cell adhesion molecules (CAMs) hsa04612 Antigen processing and presentation hsa04640 Hematopoietic cell lineage hsa04672 Intestinal immune network for IgA production |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-388841: Costimulation by the CD28 family R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-202424: Downstream TCR signaling R-HSA-202433: Generation of second messenger molecules R-HSA-168256: Immune System R-HSA-913531: Interferon Signaling R-HSA-877300: Interferon gamma signaling R-HSA-2132295: MHC class II antigen presentation R-HSA-389948: PD-1 signaling R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains R-HSA-202403: TCR signaling R-HSA-202430: Translocation of ZAP-70 to Immunological synapse |
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between HLA-DPB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between HLA-DPB1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of HLA-DPB1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of HLA-DPB1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of HLA-DPB1 in various data sets.
|
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HLA-DPB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HLA-DPB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HLA-DPB1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HLA-DPB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of HLA-DPB1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between HLA-DPB1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | HLA-DPB1 |
Name | major histocompatibility complex, class II, DP beta 1 |
Aliases | HLA-DP1B; DPB1; HLA-DP; HLA-DPB; HLA DP14-beta chain; HLA class II histocompatibility antigen, DP(W4) beta c ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting HLA-DPB1 collected from DrugBank database. |
There is no record. |